HRMY SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 24, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Harmony Biosciences Reports Q3 Financial Results, Strong WAKIX Sales and Positive BP-205 Orexin Agonist Data

Nov 4, 2026

8-K/A

Leadership transition agreements detail outgoing CEO’s consulting terms and incoming CEO’s $725,000 salary, bonus opportunity, and equity awards

Oct 30, 2026

8-K

Harmony Biosciences Announces Planned CEO Transition and Reaffirms 2026 Guidance

Oct 13, 2026

8-K

Harmony Biosciences Reports Record Q2 2026 Revenue and Positive Clinical Progress for BP-205

Aug 4, 2026

8-K

Harmony Biosciences Reports Record Q2 2026 Revenue and Announces CFO Transition

Jul 16, 2026

8-K

Harmony Biosciences Holdings, Inc. Announces Results of 2026 Annual Meeting of Stockholders

May 14, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B7

SHARE RESALE REGISTRATION | Shares amount: 8,000,000 | Share price: $31.00 | Offering amount: $248,000,000.00

Oct 31, 2024

424B7

SHARE RESALE REGISTRATION | Shares amount: 8,000,000

Oct 29, 2024

424B5

Common Stock-

Nov 9, 2021

424B4

5,348,837 Shares

Aug 19, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 25, 2025

S-3ASR

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Feb 25, 2025

S-8

Registration

Feb 22, 2024

SC TO-T/A

Registration

Oct 11, 2023

SC TO-T/A

and (y) of which the underlying shares of Company Common Stock are not validly tendered in the Offer

Oct 4, 2023

SC TO-T/A

Registration

Sep 27, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 3, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 3, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 4, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 4, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 11, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 11, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

BlackRock, Inc. (Filed by)

Oct 27, 2026

Budur Kumar (Reporting)

Sep 18, 2026

144

Form 144 - Report of proposed sale of securities

Sep 18, 2026

144

Form 144 - Report of proposed sale of securities

Sep 17, 2026

144

Form 144 - Report of proposed sale of securities

Sep 16, 2026

Budur Kumar (Reporting)

Sep 9, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Apr 15, 2025

CORRESP

Form CORRESP - Correspondence

Apr 9, 2025

LETTER

Form UPLOAD - SEC-generated letter

Mar 28, 2025

CORRESP

Form CORRESP - Correspondence

Sep 14, 2023

LETTER

Form UPLOAD - SEC-generated letter

Sep 13, 2023

CORRESP

Form CORRESP - Correspondence

Sep 12, 2023

Harmony Biosciences Holdings, Inc. HRMY · SEC Filings